18.03.2022 09:00
The three-year collaboration between RocketVax AG and a consortium of renowned research institutions from Bern, Geneva, Berlin and Riems (Germany) will bring two second generation vaccine candidates against SARS-CoV-2 into phase I clinical trials. Funded by the German Research Foundation, Innosuisse, the Canton of Basel-Stadt, and private investors, RocketVax provides support in setting up production and in upscaling.